Abstract
Omega-3 polyunsaturated fatty acids (ω-3 PUFAs) from marine origin have been strongly associated with cardiovascular protection, even at low doses (< 1g/d). Despite the research performed in this promising area, basic aspects, such as the ideal doses and the mechanisms by which ω-3 PUFAs act, are not precisely defined. The best known biological property of ω-3 PUFAs is their hypotriglyceridemic effect, but other cardioprotective actions, such as reduction of arrhythmia susceptibility, antithrombotic, antiinflammatory and antioxidant effects, improvement of endothelial function, and delayed atherosclerosis development have received an increased interest in recent years. Some of these actions are also ascribable to high-density lipoproteins (HDL). Abundant epidemiological evidence links increasing HDL-cholesterol concentrations to cardiovascular protection. Recently, the protein cargo (proteome) of HDL particles has been attributed a key role in their functionality. In this review, we summarize the main effects of ω-3 PUFAs on HDL-cholesterol, HDL subfractions, and its main proteins, apolipoproteins (apo) AI and AII. The shared cardioprotective actions of ω-3 PUFAs and HDL are reviewed as well.
Keywords: Omega-3 PUFAs, high-density lipoprotein, eicosapentaenoic acid and docosahexaenoic acid, atherosclerosis, apolipoproteins, proteome, CVD, coagulation, fibrinolysis
Current Vascular Pharmacology
Title:Omega-3 Fatty Acids and HDL. How Do They Work in the Prevention of Cardiovascular Disease?
Volume: 10 Issue: 4
Author(s): Elena Burillo, Paula Martin-Fuentes, Rocio Mateo-Gallego, Lucia Baila-Rueda, Ana Cenarro, Emilio Ros and Fernando Civeira
Affiliation:
Keywords: Omega-3 PUFAs, high-density lipoprotein, eicosapentaenoic acid and docosahexaenoic acid, atherosclerosis, apolipoproteins, proteome, CVD, coagulation, fibrinolysis
Abstract: Omega-3 polyunsaturated fatty acids (ω-3 PUFAs) from marine origin have been strongly associated with cardiovascular protection, even at low doses (< 1g/d). Despite the research performed in this promising area, basic aspects, such as the ideal doses and the mechanisms by which ω-3 PUFAs act, are not precisely defined. The best known biological property of ω-3 PUFAs is their hypotriglyceridemic effect, but other cardioprotective actions, such as reduction of arrhythmia susceptibility, antithrombotic, antiinflammatory and antioxidant effects, improvement of endothelial function, and delayed atherosclerosis development have received an increased interest in recent years. Some of these actions are also ascribable to high-density lipoproteins (HDL). Abundant epidemiological evidence links increasing HDL-cholesterol concentrations to cardiovascular protection. Recently, the protein cargo (proteome) of HDL particles has been attributed a key role in their functionality. In this review, we summarize the main effects of ω-3 PUFAs on HDL-cholesterol, HDL subfractions, and its main proteins, apolipoproteins (apo) AI and AII. The shared cardioprotective actions of ω-3 PUFAs and HDL are reviewed as well.
Export Options
About this article
Cite this article as:
Burillo Elena, Martin-Fuentes Paula, Mateo-Gallego Rocio, Baila-Rueda Lucia, Cenarro Ana, Ros Emilio and Civeira Fernando, Omega-3 Fatty Acids and HDL. How Do They Work in the Prevention of Cardiovascular Disease?, Current Vascular Pharmacology 2012; 10 (4) . https://dx.doi.org/10.2174/157016112800812845
DOI https://dx.doi.org/10.2174/157016112800812845 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neurogenesis in Alzheimers Disease: A Realistic Alternative to Neuronal Degeneration?
Current Signal Transduction Therapy Effects of Lipid Lowering Drugs on Arterial Stiffness: One More Way to Reduce Cardiovascular Risk?
Current Vascular Pharmacology Prime Time for Lower Extremity Artery Disease
Current Vascular Pharmacology Stem Cell Therapy in Chronic Ischemic Heart Dysfunction with and Without Viability
Cardiovascular & Hematological Disorders-Drug Targets Breast Cancer: Current Developments in Molecular Approaches to Diagnosis and Treatment
Recent Patents on Anti-Cancer Drug Discovery Does a Pro-Inflammatory Process Precede Alzheimers Disease and Mild Cognitive Impairment?
Current Alzheimer Research Apo-E4 Allele in Conjunction with Aβ42 and Tau in CSF: Biomarker for Alzheimers Disease
Current Alzheimer Research Wounds Difficult to Heal: An Effective Treatment Strategy
Current Vascular Pharmacology The Early Involvement of the Innate Immunity in the Pathogenesis of Lateonset Alzheimers Disease: Neuropathological, Epidemiological and Genetic Evidence
Current Alzheimer Research Male Adolescent Treatment Outcome: A Case Series of Eight Men Treated with Psychoanalytic Psychotherapy
Adolescent Psychiatry Ox-LDL Particles: Modified Components, Cellular Uptake, Biological Roles and Clinical Assessments
Cardiovascular & Hematological Disorders-Drug Targets Fluid-fluid Levels in Musculoskeletal Tumor Imaging
Current Medical Imaging Establishment of a Secondary Screening Assay for P/Q-Type Calcium Channel Blockers
Combinatorial Chemistry & High Throughput Screening Diagnosis and Treatment of Alzheimers Disease
Current Medicinal Chemistry - Central Nervous System Agents Long-term Outcomes of Mitral Valve Repair Versus Replacement for Degenerative Disease: A Systematic Review
Current Cardiology Reviews Renal Effects of Non-Steroidal Anti-Inflammatory Drugs and Selective Cyclooxygenase-2 Inhibitors
Current Pharmaceutical Design Multifaceted Effects of Delta Opioid Receptors and DADLE in Diseases of the Nervous System
Current Drug Discovery Technologies From Blood-to-Brain: Regulating the Permeability of the Blood-Brain Barrier
Current Psychopharmacology Clearance of Beta-Amyloid in the Brain
Current Medicinal Chemistry Angiotensin Peptides as AT2 Receptor Agonists
Current Protein & Peptide Science